Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice

CONCLUSIONS: Our multi-omics study confirmed previously known pathways involved in imatinib anticancer activity as well as correlated imatinib-relevant downregulation of expression of purine biosynthesis pathway genes with the reduction of respectful metabolites. Furthermore, considering the importance of the purine biosynthesis pathway for cancer proliferation, we identified a potentially novel mechanism for the anti-tumour activity of imatinib. Based on the results, we hypothesise metabolic modulations aiming at the reduction in purine and pyrimidine pool may ensure higher imatinib efficacy or re-sensitise imatinib-resistant tumours.PMID:36774883 | DOI:10.1016/j.tranon.2023.101632

Source: Translational Oncology - February 12, 2023 Category: Cancer & Oncology Authors: Szymon Macioszek Danuta Dudzik Rafa ł Bartoszewski Tomasz Stokowy Diether Lambrechts Bram Boeckx Agnieszka Wozniak Patrick Sch öffski Micha ł J Markuszewski Source Type: research